← SELLAS Life Sciences Group, Inc. (SLS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
SELLAS Life Sciences Group, Inc. (SLS)
Pharmaceutical Preparations · market cap $2.3B · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
SELLAS Life Sciences Group (SLS) is a clinical-stage oncology company with a market cap of ~$2.4B built almost entirely around galinpepimut-S (GPS), a WT1-targeting cancer immunotherapy in Phase 3 for Acute Myeloid Leukemia. The company carries $107.1M in cash (~36 months of runway at the current burn rate) and no revenue, with a short interest of 34% of float signaling significant market skepticism about its valuation relative to clinical stage.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2026-12-30 (est.)Phase 2 · SLS009imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Galinpepimut-S | Phase 3 | Acute Myeloid Leukemia |
| Galinpepimut-S + Montanide + GM-CSF | Phase 2 | Malignant Pleural Mesothelioma |
| SLS009 | Phase 2 | Hematologic Malignancies |
Price & technical context
3-month
-24.4%
6-month
+169.1%
12-month
+603.7%
52-wk range
$1.39–$15.46
vs 50-day MA
-8.1%
vs 200-day MA
+46.5%
Realized vol
103.7%
Max drawdown
-37.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SLS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.